Antibody-based therapy for type-2 diabetes

• Unité de recherche: INNOSUISSE
• Numéro de projet: 13750.1;12 PFFLE-LS
• Titre du projet anglais: Antibody-based therapy for type-2 diabetes

Description succincte (Allemand)

Antibody-based therapy for type-2 diabetes

Description succincte (Anglais)

Antibody-based therapy for type-2 diabetes

Résumé des résultats (Abstract) (Allemand)

The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.

Résumé des résultats (Abstract) (Anglais)

The project focuses on the development of an immunotherapy targeting toxic aggregates of islet amyloid polypeptide which are associated with the loss of pancreatic beta-cells in type-2 diabetes patients. Combining Neurimmune¿s expertise in the discovery and validation of human antibodies and academic partners' know-how in diabetes and amyloidosis research, the joint program is aimed at providing in vivo proof-ofconcept for this novel therapeutic strategy for type-2 diabetes.